Date: Monday, November 9, 2015
Session Type: ACR Concurrent Abstract Session
Session Time: 2:30PM-4:00PM
Background/Purpose: Corticosteroids, currently the mainstay of uveitis treatment, are associated with adverse events and are not always fully effective. Multiple reports describe the use of biologics, including adalimumab (ADA), in the management of noninfectious uveitis, but there is a paucity of level 1 evidence to support efficacy of these drugs. This study assessed ADA efficacy and safety in patients with active, noninfectious uveitis despite the use of systemic corticosteroid therapy.
Methods: A total of 217 patients aged ≥18 years with active, noninfectious intermediate, posterior, or panuveitis (characterized by active, inflammatory chorioretinal or retinal vascular lesions; anterior chamber [AC] cell grade ≥2+; and/or vitreous haze [VH] grade ≥2+) despite ≥2 weeks of prednisone (10–60 mg/d) were randomized 1:1 to receive placebo or ADA (80 mg loading dose, 40 mg at week 1, followed by 40 mg every other week) for ≤80 weeks. All patients received a mandatory prednisone burst and taper schedule. Primary endpoint was time to treatment failure (TF) at or after Week 6 in ≥1 eye: new, active, inflammatory vascular lesions relative to baseline; worsening of BCVA by ≥15 letters; inability to achieve ≤0.5+ AC or VH grades at Week 6; 2-step increase in AC cell or VH grades after Week 6. Secondary endpoints included change in AC cell grade, VH grade, and logMAR BCVA; time to macular edema (ME); and percent change in central retinal thickness (CRT), all measured from best state achieved before Week 6 to final visit. Area under the curve (AUC) was calculated for AC cell, VH grade, and logMAR BCVA plotted against time.
Results: Patients receiving ADA were less likely to experience TF (HR=0.50; 95% CI, 0.36-0.70; P<0.001), with fewer associated TF causes. Median time to TF was 13 weeks for placebo and 24 weeks for ADA. Statistically significant differences in favor of ADA versus placebo for mean change from best state before Week 6 to the final visit were met for AC cell grade (P=0.011), VH grade (P<0.001), logMAR BCVA (P=0.003), and CRT (P=0.020). A statistically significant difference was not observed for time to OCT evidence of cystoid ME using the full analysis set. In a post-hoc analysis of ME (definition based on CRT, center point thickness 260-340 μm) performed on a subset of patients without macular hole or retinal detachment, ME risk was reduced by 67% in the ADA group versus placebo (HR=0.33; 95% CI, 0.12-0.90; P=0.023). Mean AUC values were significantly higher in the ADA group versus placebo, suggesting better and more durable control of AC cell (mean difference 34.3, 95%CI, 9.2-59.3; P=0.008), VH grade (35.4, 95%CI, 11.3-59.4; P=0.004), and improvement in logMAR BCVA (26.2, 95%CI, 7.0-45.3; P=0.008). Adverse event data were consistent with the safety profile across approved indications for ADA.
Conclusion: In patients with active, noninfectious intermediate, posterior, or panuveitis despite the use of corticosteroids, ADA significantly lowered the risk for recurrence of uveitic activity and BCVA loss. ADA also reduced the risk of developing ME in patients without preexisting macular pathology. The safety profile was consistent with the known safety profile across approved ADA indications.
To cite this abstract in AMA style:Brezin AP, Kestelyn P, Van Calster J, Jaffe GJ, Thorne JE, Scales D, Franco P, Dick AD, Nguyen QD, Suhler EB, Camez A, Song AP, Kron M, Tari S, Rosenbaum JT, Heiligenhaus A. Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/adalimumab-in-patients-with-active-noninfectious-uveitis-using-high-dose-corticosteroids/. Accessed April 24, 2018.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - http://acrabstracts.org/abstract/adalimumab-in-patients-with-active-noninfectious-uveitis-using-high-dose-corticosteroids/